The Phase I trial is designed to assess the safety, tolerability and initial efficacy of altiratinib in these patients.
In preclinical studies, altiratinib has been shown to exhibit high potency and selectivity for inhibiting MET, TIE2, VEGFR2, and TRK kinases.
The company said that in preclinical cancer models, altiratinib has shown impressive activity against multiple tumors including melanoma, ovarian, glioblastoma, colorectal, gastric and breast cancers.
Deciphera president and chief executive officer Michael Taylor said the company is happy to advance altiratinib into clinical development based on the encouraging preclinical data demonstrated to date.
"With its balanced inhibition of key kinase mechanisms, including MET, TIE2, VEGFR2 and TRK, altiratinib was designed to address both tumor cells and the tumor microenvironment by providing high potency and inhibition against cancer cells, metastases, and invasiveness," Taylor said.
"We look forward to reporting on our progress with altiratinib, which has the potential to provide an important new option for cancer patients with solid tumors."
Altiratinib is designed to exhibit high potency and selectivity for inhibiting MET, TIE2, VEGFR2 and TRK kinases in cellular and in vivo cancer studies.